ORGANOGENESIS INC
3, 1998-11-20
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: ORACLE CORP /DE/, 3, 1998-11-20
Next: NATIONWIDE HEALTH PROPERTIES INC, 424B3, 1998-11-20



<PAGE>
 

 
                    U.S. SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

FORM 3                                                      OMB APPROVAL
                                                   -----------------------------
                                                   OMB NUMBER:  3235-0104
                                                   Expires:  September 30, 1998
                                                   Estimated average burden
                                                   hours per response ...... 0.5
                                                   -----------------------------


            INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES



    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
      Section 17(a) of the Public Utility Holding Company Act of 1935 or
              Section 30(f) of the Investment Company Act of 1940




1. Name and Address of Reporting Person*

Erani                                Albert             
- --------------------------------------------------------------------------------
  (Last)                             (First)                         (Middle)

c/o Organogenesis Inc.
150 Dan Road
- --------------------------------------------------------------------------------
                                    (Street)

Canton                               MA                               02021
- --------------------------------------------------------------------------------
  (City)                             (State)                          (Zip)


- --------------------------------------------------------------------------------
2. Date of Event Requiring Statement (Month/Day/Year)
   11/10/98

- --------------------------------------------------------------------------------
3. IRS or Social Security Number of Reporting Person (Voluntary)
    

- --------------------------------------------------------------------------------
4. Issuer Name and Ticker or Trading Symbol
   Organogenesis Inc. "ORG"

- --------------------------------------------------------------------------------
5. Relationship of Reporting Person to Issuer 
       (Check all applicable)


             x    Director                         10% Owner
           -----                           ------ 

                  Officer (give                    Other (Specify
           -----           title below)    ------         below)

 
                   ----------------------------------

- --------------------------------------------------------------------------------
6. If Amendment, Date of Original   (Month/Day/Year)


- --------------------------------------------------------------------------------

- --------------------------------------------------------------------------------
7. Individual or Joint/Group Filing (Check Applicable Line)

    x   Form filed by One Reporting Person
   ---

        Form filed by More than One Reporting Person
   ---  
- --------------------------------------------------------------------------------

<TABLE> 
<CAPTION> 
                                      Table 1 -- Non-Derivative Securities Beneficially Owned

1. Title of Security          2. Amount of Securities         3. Ownership Form:        4. Nature of Indirect Beneficial Ownership
   (Instr. 4)                    Beneficially Owned              Direct (D) or             (Instr. 5)
                                 (Instr. 4)                      Indirect (I)
                                                                 (Instr. 5) 
<S>                           <C>                              <C>                      <C> 
Common Stock                  1,342,508 (1)                      (D)(I) (1)             See Note 1
- --------------------------    ---------------------------      -----------------        ------------------------------------------



- --------------------------    ---------------------------      -----------------        ------------------------------------------

- --------------------------    ---------------------------      -----------------        ------------------------------------------

- --------------------------    ---------------------------      -----------------        ------------------------------------------

- --------------------------    ---------------------------      -----------------        ------------------------------------------

- --------------------------    ---------------------------      -----------------        ------------------------------------------

- --------------------------    ---------------------------      -----------------        ------------------------------------------

- --------------------------    ---------------------------      -----------------        ------------------------------------------

- --------------------------    ---------------------------      -----------------        ------------------------------------------

- --------------------------    ---------------------------      -----------------        ------------------------------------------

- --------------------------    ---------------------------      -----------------        ------------------------------------------
</TABLE> 

Reminder: Report on a separate line for each class of securities beneficially 
          owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v)

                  (Print or Type Responses)                      
                                                                 

                                                                         (Over)
                                                                SEC 1473 (7-96)

<PAGE>
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

FORM 3 (continued)   

<TABLE> 
<CAPTION> 

        Table II -- Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security   2. Date Exer-   3. Title and Amount of Securities  4. Conversion   5. Ownership    6. Nature of 
   (Instr. 4)                        cisable and     Underlying Derivative Security     or Exercise     Form of         Indirect
                                     Expiration     (Instr. 4)                          Price of        Derivative      Beneficial
                                     Date                                               Derivative      Security:       Ownership
                                    (Month/Day/                                         Security        Direct (D)     (Instr. 5)
                                     Year)                                                              or
                                  ------- ------- ---------------------------------                     Indirect (I)
                                  Date    Expira-                            Amount                    (Instr. 5)
                                  Exer-   tion                               or
                                  cisable Date             Title             Number
                                                                             of
                                                                             Shares
- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 
<S>                               <C>     <C>     <C>                        <C>    <C>             <C>             <C> 
Option to Purchase (2)            (3)     11/10/08 Common Stock              15,000 $13.00          D 
- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 

- -------------------------------   ------- -------  ------------------------  ------ --------------- --------------- ------------- 
</TABLE> 
Explanation of Responses:
(1) Includes 23,625 shares beneficially owned by Mr Erani's wife, Barbara, and 
    60,118 shares held in trust by Mr Erani for the benefit of his children.
(2) Company may withhold stock upon option exercise to satisfy withholding 
    obligation.
(3) Option shares vest in installments of 20% each year over a period of five 
    years beginning on the first anniversary of the date of grant.


**Intentional misstatements or omissions of facts constitute Federal Criminal 
  Violations.
  
  See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).



                              /s/ Albert Erani                   11/19/98
                              _______________________________    ______________
                              **Signature of Reporting Person         Date


Note: File three copies of this Form, one of which must be manually signed. If 
      space is insufficient, 
      See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained 
in this form are not required to respond unless the form displays a currently 
valid OMB Number.



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission